GBT Announces Participation in Upcoming Investor Conferences
February 19 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in virtual fireside chats at the
following investor conferences:
- SVB Leerink 10th Annual Global
Healthcare Conference on February 26 at 2:20 p.m. ET; and
- Cowen 41st Annual Health Care Conference on March 1 at 11:40
a.m. ET. Ted W. Love, M.D., president and CEO of GBT, will also
participate in a virtual panel, Non-Malignant Hematology, at this
conference on March 1 at 2:40 p.m. ET.
The fireside chats will be webcast live from GBT’s website at
www.gbt.com in the Investors section. Replays of the webcasts will
be archived and available for one month following each
event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a P-selectin
inhibitor in development to address pain crises associated with the
disease, and GBT021601 (GBT601), the company’s next generation
hemoglobin S polymerization inhibitor. In addition, GBT’s drug
discovery teams are working on new targets to develop the next wave
of treatments for SCD. To learn more, please
visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact:Steven Immergut
(media)650.410.3258simmergut@gbt.com
Courtney
Roberts (investors)650.351.7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024